Trattamento endovescicale alternativo al BCG nel carcinoma vescicale NMI a rischio intermedio o elevato.

Translated title of the contribution: [Endovesical treatment as an alternative to BCG for intermediate or high-risk NMI bladder cancer].

Vincenzo Serretta, Renzo Colombo

Research output: Contribution to journalArticlepeer-review

Abstract

A shortage of BCG is foreseen till the end of 2013. Which will be the management of intermediate and high-risk NMI-BC if BCG will not be available? In patients harboring high-risk NMI tumors, particularly T1G3 and Tis, the first therapeutic choice is radical cystectomy. Device-assisted therapies, although showing promising results, should be considered only for selected patients. In intermediate risk patients, intravesical chemotherapy remains a legitimate option even if BCG is available. Thus, in a period of BCG shortage, intravesical chemotherapy should be offered, preferably preceded by early instillation, according to the EAU guidelines.

Translated title of the contribution[Endovesical treatment as an alternative to BCG for intermediate or high-risk NMI bladder cancer].
Original languageItalian
Pages (from-to)24-26
Number of pages3
JournalUrologia
Volume80 Suppl 21
Publication statusPublished - 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of '[Endovesical treatment as an alternative to BCG for intermediate or high-risk NMI bladder cancer].'. Together they form a unique fingerprint.

Cite this